Lipitor

Atorvastatin, the active ingredient in Lipitor, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol levels and is used in adults at risk of cardiovascular events. GNH USA supplies Lipitor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is indicated for disorders of lipid metabolism and for reducing cardiovascular risk. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Primary prevention of cardiovascular disease: reduces the risk of heart attack and stroke in patients without prior events. - Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established disease. - Mixed dyslipidemia: improves the overall lipid profile by decreasing triglycerides and raising HDL‑cholesterol.

Adverse reactions may occur with atorvastatin therapy.

Common Side Effects: - Muscle pain or weakness - Headache - Nausea or abdominal discomfort - Elevated liver enzymes - Diarrhea - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis leading to renal impairment - Severe hepatic injury - Acute pancreatitis - Allergic reactions such as rash or angioedema

Before initiating therapy, consider the following safety measures. - Liver function monitoring: assess baseline transaminases and repeat as clinically indicated. - Muscle toxicity vigilance: educate patients to report unexplained muscle pain, especially with concurrent statin use. - Drug interactions: review concomitant medications that may increase statin exposure. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Renal impairment: adjust therapy in patients with severe kidney disease. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Atorvastatin may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause dangerous increases in statin levels. - Gemfibrozil: heightens risk of myopathy and rhabdomyolysis. - Cyclosporine: significantly raises atorvastatin exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may modestly reduce absorption. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Niacin: can increase risk of muscle toxicity.